CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
树突状细胞疫苗治疗新诊断胶质母细胞瘤的疗效：随机对照研究的 Meta 分析
英文原题：The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies.
查看英文原题
The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
树突状细胞疫苗对新诊断胶质母细胞瘤的疗效仍存争议。我们进行了一项系统回顾与荟萃分析，旨在探讨树突状细胞疫苗对新诊断胶质母细胞瘤治疗效果的影响。
我们检索了PubMed、EMBASE、Web of Science、EBSCO及Cochrane图书馆数据库，时间截至2019年12月，纳入评估树突状细胞疫苗对新诊断胶质母细胞瘤疗效与安全性的随机对照试验。本荟萃分析采用随机效应模型进行。荟萃分析共纳入三项随机对照试验。
总体而言，与对照组相比，树突状细胞疫苗对新诊断胶质母细胞瘤的中位总生存期[标准化均数差，0.11；95%置信区间(CI)，-0.18至0.41；P = 0.45]、中位无进展生存期（标准化均数差，0.12；95% CI，-0.24至0.48；P = 0.50）、无进展生存率[风险比(RR)，1.29；95% CI，0.82-2.04；P = 0.27]、总生存率（RR，1.29；95% CI，0.61-2.72；P = 0.50）或神经系统疾病（RR，0.80；95% CI，0.59-1.08；P = 0.14）均无显著影响。树突状细胞疫苗可能对新诊断胶质母细胞瘤无明显获益。
展开英文摘要原文
The efficacy of dendritic cell vaccine for newly diagnosed glioblastoma remains controversial.
We conduct a systematic review and meta-analysis to explore the influence of dendritic cell vaccine on treatment efficacy for newly diagnosed glioblastoma.
We search PubMed, EMBASE, Web of science, EBSCO, and Cochrane library databases through December 2019 for randomized controlled trials assessing the efficacy and safety of dendritic cell vaccine for newly diagnosed glioblastoma. This meta-analysis is performed using the random effect model. Three randomized controlled trials are included in the meta-analysis.
Overall, compared with control group for newly diagnosed glioblastoma, dendritic cell vaccine shows no substantial effect on median overall survival [standard mean difference, 0. 11; 95% confidence interval (CI), -0. 18 to 0. 41; P = 0. 45], median progression-free survival (standard mean difference, 0. 12; 95% CI, -0. 24 to 0.
48; P = 0. 50), progression-free survival rate [risk ratio (RR), 1. 29; 95% CI, 0. 82-2. 04; P = 0. 27], overall survival rate (RR, 1. 29; 95% CI, 0. 61-2. 72; P = 0. 50), or nervous system disorders (RR, 0. 80; 95% CI, 0. 59-1. 08; P = 0. 14). Dendritic cell vaccine may provide no obvious benefits for the newly diagnosed glioblastoma.
论文信息
- 作者
- Tan L、Peng J、Liu P、Wu Q
- 第一作者单位
- Department of Neurosurgery.
- 通讯作者单位
- Department of Emergency, The First Hospital of Changsha, Hunan Province, China.China
- 文献类型
- 荟萃分析 · 系统综述
- 期刊
- Clinical neuropharmacology2021 Nov-Dec 01
- 原文标识
- PubMed 34767325 · DOI 10.1097/WNF.0000000000000452